• Patients with COVID arm or isolated urticaria with and without angioedema should be
advised that cutaneous reactions may recur with future doses, but are often milder, of shorter …

Background The coronavirus disease 2019 (COVID‐19) is associated with a wide clinical
spectrum of skin manifestations, including urticarial, vesicular, vasculitic and chilblain‐like …

Since the emergency authorization of SARS-CoV-2 vaccines, the medical literature has
been investigating the management of allergic reactions to the vaccines. Anaphylaxis has …

Since the beginning of the covid-vaccine campaign, a lot of local and systemic dermatologic
reactions happening after the administration of Coronavirus disease 2019 (COVID-19) …

Background Cutaneous reactions after severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2) vaccines are poorly characterized. Objective To describe and classify …

Background As more people become vaccinated against the SARS‐CoV‐2 virus, reports of
delayed cutaneous hypersensitivity reactions are beginning to emerge. Methods In this IRB …

In response to the COVID-19 pandemic, over 89 million doses of coronavirus vaccines have
been administered so far in the UK. An increasing number of mucocutaneous reactions are …

Methods A retrospective chart review was conducted for patients seen in the allergy clinic
between December 2020 and May 2021 for COVID-19 vaccine counseling. Details of …

Background: Rashes after coronavirus disease of 2019 (COVID-19) mRNA vaccinations
occur with typical and atypical presentations. Objective: The goal of this article is to increase …

Recently, Food and Drug Administration and European Medicines Agency approved the
BNT162b2 messenger RNA (mRNA) vaccine for the prevention of severe acute respiratory …